| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $7.6M | — | +25.6% |
| SG&A Expense | $4.3M | — | -1.5% |
| Operating Income | -$11.8M | — | -14.3% |
| Interest Expense | $0 | — | -100.0% |
| Net Income | -$10.9M | — | -6.5% |
| EPS (Basic) | -$0.46 | — | +81.7% |
| EPS (Diluted) | -$0.46 | — | +81.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $34.4M | -64.9% | -65.9% |
| Short-term Investments | $62.8M | +215.1% | — |
| Current Assets | $98.5M | -17.1% | -3.6% |
| Total Assets | $109.8M | -9.8% | +6.5% |
| Current Liabilities | $8.1M | -16.8% | +13.1% |
| Total Liabilities | $41.2M | -3.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$11.6M | — | -55.6% |
| Investing Cash Flow | -$50.4M | — | — |
| Financing Cash Flow | -$1.7M | — | -101.6% |
| +5.2% |
| Stockholders' Equity | $68.6M | -13.0% | +7.3% |